Legend Biotech Corporation
19.27USD
+0.3700 (+1.96%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on LEGN.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.01▼ | $0.1 | 0 | 0 |
| Next quarter | $0.09▼ | $0.16 | 0 | 0 |
| Current year | -$0.01▼ | $0.3 | 0 | 0 |
| Next year | $0.68▼ | $1.21 | 0 | 0 |
Beat in 1 of the last 3
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.28 | $0.32 | +0.04 (+14.3%) |
| 2025-12-31 | $0.19 | -$0.16 | -0.35 (-184.4%) |
| 2025-09-30 | -$0.19 | -$0.22 | -0.04 (-18.9%) |
147 ratings from 23 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $74 $68 | Oct 13, 2026 |
| JP Morgan | Maintained | Neutral | $35 $33 | Oct 9, 2026 |
| RBC Capital | Maintained | Outperform | $58 $56 | Oct 8, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $65 | Sep 30, 2026 |
| Barclays | Maintained | Overweight | $78 $74 | Sep 11, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $65 | Sep 4, 2026 |
| Morgan Stanley | Maintained | Overweight | $48 $49 | Aug 12, 2026 |
| TD Cowen | Maintained | Hold | $29 $24 | Aug 12, 2026 |
| Oppenheimer | Downgraded from Outperform | Perform | $75 $40 | Aug 12, 2026 |
| RBC Capital | Maintained | Outperform | $59 $58 | Aug 12, 2026 |
| Barclays | Maintained | Overweight | $80 $78 | Aug 12, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $65 | Jul 28, 2026 |
| RBC Capital | Maintained | Outperform | $63 $59 | Jul 27, 2026 |
| UBS | Downgraded from Buy | Neutral | $49 $28 | Jul 24, 2026 |
| RBC Capital | Maintained | Outperform | $64 $63 | Jul 7, 2026 |
| UBS | Maintained | Buy | $31 $49 | Jun 3, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $50 $65 | Jun 3, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $50 | May 18, 2026 |
| TD Cowen | Maintained | Hold | $21 $29 | May 13, 2026 |
| Morgan Stanley | Maintained | Overweight | $49 $48 | May 13, 2026 |
| RBC Capital | Maintained | Outperform | $62 $64 | May 13, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $50 | Apr 21, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $50 | Apr 15, 2026 |
| Morgan Stanley | Maintained | Overweight | $50 $49 | Mar 11, 2026 |
| RBC Capital | Maintained | Outperform | $66 $62 | Mar 11, 2026 |
14 filings from 11 insiders · 9 buy / 4 sell over 6m
Officers and directors of LEGN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sanders Corazon (Corsee) D.Director | Sell | 27.4k | $9.46 | $259k | Sep 29, 2026 |
| Sanders Corazon (Corsee) D.Director | Grant | 21.0k | — | — | Sep 24, 2026 |
| Heyman Tomas J.Director | Grant | 21.0k | — | — | Sep 24, 2026 |
| Ji Darren XiaohuiDirector | Grant | 28.3k | — | — | Sep 24, 2026 |
| Casey Patrick JohnDirector | Grant | 21.0k | — | — | Sep 24, 2026 |
| Salovey PeterDirector | Grant | 28.3k | — | — | Sep 24, 2026 |
| Mao LiDirector | Grant | 21.0k | — | — | Sep 24, 2026 |
| Santos Carlos EOfficer, Chief Financial Officer | Grant | 19.7k | — | — | Sep 21, 2026 |
| Santos Carlos EOfficer, Chief Financial Officer | Sell | 5.4k | $9.14 | $50k | Sep 21, 2026 |
| Zhang IngridOfficer, Chief Executive Officer | Grant | 1.13M | — | — | Sep 15, 2026 |
| BASH ALANChief Executive Officer | Grant | 4.9k | — | — | Aug 14, 2026 |
| CASEY PATRICK JOHN PH.D.Director | Sell | 6.0k | $28.88 | $173k | Jun 30, 2026 |
| HUANG YINGChief Executive Officer | Gift | 3.4k | — | — | Jun 30, 2026 |
| HUANG YINGChief Executive Officer | Sell | 5.6k | $28.43 | $158k | Jun 25, 2026 |
No analyst notes on LEGN yet.
Analyst Ratings
13 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 3 | 5 | 0 | 0 | Buy2.00 |
| 1 mo ago | 5 | 3 | 5 | 0 | 0 | Buy2.00 |
| 2 mo ago | 5 | 5 | 5 | 0 | 0 | Buy2.00 |
| 3 mo ago | 5 | 6 | 4 | 0 | 0 | Buy1.93 |
Members whose judged calls on LEGN have played out most reliably.
No settled calls on LEGN yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice